Siltuximab

国际站：Siltuximab

CAS：541502-14-1

品牌：MedChemExpress (MCE)

存储条件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性：Siltuximab 是一种抗IL-6 (interleukin-6) 单克隆抗体，具有抗肿瘤活性。 Siltuximab 可用于多中心 Castleman 病 (MCD) 和 COVID-19 研究^[1][2][3]。 

体内：Siltuximab (intraperitoneal injection; 10 mg/kg; 3 times per week) 在异种移植小鼠模型中抑制肺癌细胞的生长^[1]。Siltuximab (intraperitoneal injection; 20 mg/kg) ; 每周两次; 6 w) 在异种移植模型中抑制 MCF-7 肿瘤的生长^[4]。

参考文献：[1]. Karkera J, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011 Sep 15;71(13):1455-65.[2]. Khan FA, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12.[3]. Song L, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol. 2014 Jul;9(7):974-982.[4]. Casneuf T, et al. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press). 2016 Feb 3;8:13-27.